CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 21 enrolled
Drug / intervention
Light Adjustable lens (LAL) and Light Delivery Device (LDD)device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03729024
NCT03729024N/ACompleted
CompareCT.gov

A Single Center Exploratory Study to Evaluate Uncorrected Distance Vision and Quality of Vision After Light Treatments of an Implanted RxSight Light Adjustable Lens (RXLAL) With The Light Delivery Device (LDD) in Subjects With Preoperative Corneal Astigmatism

RxSight, Inc.·interventional·Posted Nov 2, 2018·Updated Aug 6, 2021

In Brief

A clinical study evaluating Light Adjustable lens (LAL) and Light Delivery Device (LDD) for Aphakia and Cataract. Completed, enrolled 21 participants across 1 site.

Detailed Summary

The objective of this study is to evaluate uncorrected distance vision and quality of vision as measured by the McAlinden QoV questionnaire 3 months following the final lock-in treatment of the implanted RxSight Light Adjustable Lens (RxLAL) with the Light Delivery Device (LDD) in subjects with preoperative keratometric astigmatism. This is an exploratory study. No primary effectiveness endpoints will be defined.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAphakia, Cataract
CountriesMexico
Collaborators--

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedNov 2, 2018
Enrollment StartJan 26, 2018
Primary CompletionApr 15, 2019
Study CompletionFeb 4, 2020
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 7.7 years ago

Interventions

Light Adjustable lens (LAL) and Light Delivery Device (LDD)device

Primary and Fellow eyes will receive Light adjustable lens with Light delivery Device treatments